Ultragenyx Pharmaceutical Inc. announced it has in-licensed an enzyme replacement therapy program to treat MPS VII

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced it has in-licensed an enzyme replacement therapy program from St. Louis University to treat MPS VII. See the full press release for more details.

This entry was posted in News. Bookmark the permalink.

Comments are closed.